TLR/MyD88-activating agonists such as MPLA and CpG are promising candidates to harness the potential of trained immunity whereby innate leukocytes are primed to mount a robust response to a broad array of pathogens, allowing for containment of a local infection and elimination prior to development of life-threatening sepsis. The gene discussed is MYD88; the disease is Sepsis.